Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

482
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
482
Accessory Structures of the Eye01:17

Accessory Structures of the Eye

1.3K
Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...
1.3K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

402
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
402

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Socioeconomic status in Behçet's syndrome.

Clinical and experimental rheumatology·2026
Same author

Potential Confounding by Weight Loss: Comment on the article by Jorge et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A critical look at the evolution of randomized controlled trials: new and old ethical issues.

Current opinion in immunology·2026
Same author

Evaluation of Optical Coherence Tomography Angiography Parameters in Pulmonary, Ocular and Extrapulmonary Sarcoidosis.

Ocular immunology and inflammation·2026
Same author

Risk of major organ involvement in Behçet's patients with mucocutaneous onset: data from the AIDA Network Registry.

Rheumatology (Oxford, England)·2025
Same author

The Risk of Developing Ocular Involvement Among Behçet's Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet's Disease Registry.

Ophthalmology and therapy·2025

Related Experiment Video

Updated: May 16, 2025

Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.2K

Behçet syndrome with eye involvement.

Didar Ucar1,2, Sinem N Esatoglu2,3

  • 1Department of Ophthalmology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society
|April 4, 2025
PubMed
Summary

Behçet

Keywords:
Behçet syndrometreatmentuveitis

More Related Videos

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.2K
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
06:29

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

2.2K

Related Experiment Videos

Last Updated: May 16, 2025

Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.2K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.2K
Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
06:29

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

2.2K

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Behçet's uveitis (BU) is a severe ocular manifestation of Behçet syndrome.
  • Early diagnosis and prompt management are vital to prevent vision loss.

Purpose of the Study:

  • To review current management strategies for Behçet's uveitis.
  • To discuss the role of immunosuppressive and biologic agents.
  • To explore future therapeutic potential.

Main Methods:

  • Literature review of studies on Behçet's uveitis management.
  • Analysis of treatment outcomes with various immunosuppressive and biologic therapies.
  • Discussion of diagnostic and monitoring techniques.

Main Results:

  • Ocular examination is critical for Behçet syndrome diagnosis and BU detection.
  • Combined immunosuppressants and glucocorticoids are standard initial treatment.
  • Biologic agents are effective, particularly for high-risk patients.

Conclusions:

  • Effective management of BU requires rapid inflammation suppression and relapse prevention.
  • Fluorescein angiography is essential for monitoring remission during therapy tapering.
  • Janus kinase inhibitors represent a promising future treatment avenue.